» Articles » PMID: 25393804

Regulatory T-cell and T-helper 17 Balance in Chronic Lymphocytic Leukemia Progression and Autoimmune Cytopenias

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2014 Nov 14
PMID 25393804
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The reasons for progression and autoimmune cytopenias (AIC) in chronic lymphocytic leukemia (CLL) are not entirely clear, with previous studies suggesting a role for regulatory T-cells (Treg). In this study we prospectively studied Treg (CD3+CD4+CD25highCD127low), interleukin-10 (IL-10) producing Treg and T-helper 17 (Th17) (CD3+CD4+IL-17+) cells in 40 treatment-naive patients with CLL. The percentage of Th17 and not Treg cells was significantly higher in the AIC cohort than in those without AIC (p<0.0001). The Treg:Th17 ratio was skewed in favor of Th17 in the AIC cohort (p=0.02). Th17 cells are responsible for AIC of CLL. Analysis of lymph-node aspirates showed that the percentage of Treg and IL-10 expression in Treg and not Th17 was significantly higher than in peripheral blood (p<0.01). Treg cells play a major role in the microenvironment where disease progression occurs. This shows the importance of maintaining the Treg:Th17 equilibrium, for imbalance leads to CLL progression or AIC.

Citing Articles

Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion.

Yildirim C Mol Biol Rep. 2024; 51(1):571.

PMID: 38662155 DOI: 10.1007/s11033-024-09563-w.


Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration.

Oyama T, Yasunaga M, Jona M, Nishikawa M, Yatomi Y, Honda A J Clin Exp Hematop. 2023; 63(3):187-192.

PMID: 37635085 PMC: 10628828. DOI: 10.3960/jslrt.23023.


Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.

Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J Leukemia. 2023; 37(7):1464-1473.

PMID: 37202442 PMC: 10195665. DOI: 10.1038/s41375-023-01891-3.


An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies.

Khan S, Allsup D, Molica S Front Oncol. 2023; 13:1135812.

PMID: 37091176 PMC: 10117948. DOI: 10.3389/fonc.2023.1135812.


The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?.

Gamal W, Sahakian E, Pinilla-Ibarz J Blood Adv. 2022; 7(11):2401-2417.

PMID: 36574293 PMC: 10238851. DOI: 10.1182/bloodadvances.2022008985.